Please login to the form below

Not currently logged in
Email:
Password:

Amgen veteran Kurt Gustafson joins Spectrum as CFO

Biotech also creates new senior financial position for Brett Scott

Spectrum Kurt GustafsonSpectrum Pharmaceuticals has appointed Kurt Gustafson as its executive VP, chief financial officer and principal accounting officer.

He joins Spectrum from fellow US biotech Halozyme Therapeutics, where he served as VP and chief financial officer.

Prior to this role, he spent more than 18 years at Amgen, holding such positions as chief financial office of Amgen International and VP finance.

In addition to Gustafson's appointment, Spectrum also announced that the company's senior VP and acting chief financial officer Brett Scott has been appointed to the newly-created role of senior VP of finance.

Dr Rajesh Shrotriya, chairman, CEO and president of Spectrum, explained why the company had created the new role and appointed Gustafson.

"We believe this is a time of rapid growth at Spectrum, and the business is becoming more complex,” he said.

“Kurt brings in over 20 years of experience in finance and is a key addition to our already strong management team. We look forward to working with Kurt as we continue to build our business and execute our goals."

7th June 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics